Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

RAB0521

Sigma-Aldrich

Bovine IL2 / Interleukin-2 ELISA Kit

for serum, plasma and cell culture supernatants

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
41116158
NACRES:
NA.32

Reattività contro le specie

bovine

Confezionamento

kit of 96 wells (12 strips x 8 wells)

tecniche

ELISA: suitable

input

sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL

Metodo di rivelazione

colorimetric

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Informazioni sul gene

bovine ... IL2(280822)

Categorie correlate

Descrizione generale

This ELISA antibody pair detects bovine Interleukin-2.

Applicazioni

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Altre note

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

I componenti del kit sono disponibili anche separatamente

N° Catalogo
Descrizione
SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

Pittogrammi

Corrosion
GHS05

Avvertenze

Warning

Indicazioni di pericolo

H290

Consigli di prudenza

P234 - P390

Classi di pericolo

Met. Corr. 1

Codice della classe di stoccaggio

8A - Combustible corrosive hazardous materials

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Francesco Nannini et al.
Scientific reports, 10(1), 19168-19168 (2020-11-07)
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the advantage of in vivo affinity-maturation of V regions prior to library
Liping Qiu et al.
Small (Weinheim an der Bergstrasse, Germany), 14(15), e1703539-e1703539 (2018-03-02)
The activation of tumor-specific effector immune cells is key for successful immunotherapy and vaccination is a powerful strategy to induce such adaptive immune responses. However, the generation of effective anticancer vaccines is challenging. To overcome these challenges, a novel straight-forward
Zhengping Hu et al.
Scientific reports, 8(1), 217-217 (2018-01-11)
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.